Advisory for Aug. 23, 2009
UCLA to host conference on revolutionary and controversial new strategy to combat HIV
Meeting precedes the National HIV Prevention Conference
WHAT: Pre-exposure prophylaxis (PrEP) is a revolutionary-and some would say controversial--new strategy for combating HIV. With PrEP, HIV-negative people take antiretroviral drugs prior to potential exposure to the virus to reduce the risk of infection. Results from PrEP clinical trials are expected within the year. UCLA's Center for HIV Identification, Prevention and Treatment Services (CHIPTS) will co-host "Preparing for PrEP: A Stakeholder's Dialogue," a one-day conference comprising researchers, policy makers, providers, consumers and community representatives who will explore how PrEP could impact HIV prevention efforts if it proves to be efficacious. This conference is a satellite meeting of, and precedes, the U.S. Centers for Disease Control and Prevention's 2009 National HIV Prevention Conference in Atlanta, being held from August 23 to 26. Other conference sponsors are the National Institute of Mental Health (NIMH), the UCLA Program in Global Health, the Global Campaign for Microbicides, the Forum for Collaborative HIV Research, the Black AIDS Institute, AIDS Project LA (APLA), Community HIV/AIDS Mobilization Project (CHAMP), Project Inform, AIDS Vaccine Advocacy Coalition (AVAC), and the National Alliance of State & Territorial AIDS Directors (NASTAD)
For more details about the "Preparing for PrEP" conference, visit http://chipts.ucla.edu/events/conferences/PrEP/index.asp
WHO: o Mary Jane Rotheram-Borus, director of CHIPTSo Andrew D. Forsyth, project officer, Prevention and Behavioral Research Branch, NIMHo Thomas J. Coates, co-director, CHIPTS international core and director, UCLA Program in Global Health.o Connie Celum, professor of global health and medicine, University of Washington and principal investigator, Partners PrEP Trialo Kevin Cranston, director, Bureau of Infectious Disease, Massachusetts Department of Public Healtho Craig Washington, prevention programs director, AID Atlantao Kevin Fenton, director, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Centers for Disease Control and Preventiono Jeffrey Crowley, director, Office of National AIDS Policyo Julie Davids, senior consultant, CHAMP and co-chair, Federal AIDS Policy Partnership (FAPP)o Kevin Farrell, executive director, CHIPTSo Lynwood Miller, study coordinator/research clinician, AIDS Research Consortium of Atlantao David France, journalist/freelance writero Linda Villarosa, author/journalist/freelance writero Kenyon Farrow, interim executive director, Queers for Economic Justice and policy institute fellow, National Gay & Lesbian Taskforceo Dazon Dixon Diallo, president and founder, Sisterlove Inc.o Stephen Simon, director, LA City AIDS Coordinator's Officeo Camille Abrahams, director, African American Capacity Building Initiative, Harm Reduction Coalitiono Trina Scott, program manager, Young Women of Color Initiative, Advocates for Youtho Judy Auerbach, vice president, Science & Public Policy, San Francisco AIDS Foundationo Dawn Smith, associate chief for science, epidemiology branch, Division of HIV/AIDS Prevention-Surveillance and Epidemiology, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Preventiono Kenneth Mayer, professor of medicine and community health and director of the Brown University AIDS Programo Deirdre Grant, program manager, AVAC: Global Advocacy for HIV Prevention.
WHEN: 7:30 a.m. to 3:30 p.m. Sunday, Aug. 23.
WHERE: Hyatt Regency Atlanta, 265 Peachtree Street NE, Atlanta
BACKGROUND: The Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) is a collaboration of researchers from UCLA, Charles Drew University of Medicine and Science, Friends Research Institute, RAND, and the broader Los Angeles community working to enhance our collective understanding of HIV research and to promote early detection, effective prevention, and treatment programs for HIV. Funded by the National Institute of Mental Health, CHIPTS serves as a bridge among researchers, government, service providers, and people with HIV in responding to the changes in the HIV epidemic and in shaping sound public policy. For more information, visit the Center's Web site at http://chipts.ucla.edu/ RESERVATIONS: Contact Kevin Farrell at (310) 794-6272 through Thursday, Aug. 20. After that date, please use mobile phone (707) 328-2828
MEDIA CONTACT: Enrique Rivero, UCLA Health Sciences Media Relations email@example.com, (310) 794-2273.
On-Site: Kevin Farrell, Executive Director, CHIPTS. Mobile phone (707) 328-2828
LOS ANGELES — Early results from a new, pioneering chimeric antigen receptor (CAR) T cell immunotherapy trial led by researchers at the UCLA Jonsson Comprehensive Cancer Center found using a bilateral attack instead of the conventional single-target approach helps minimizes treatment resistance, resulting in long-lasting remission for people with non-Hodgkin's B-cell lymphoma that has come back or has not responded to treatment.
Learn more about myUCLAhealth